Heart failure & cardiomyopathiesCohort study
Eligibility for Vericiguat in a Real-World Heart Failure Population According to Trial, Guideline and Label Criteria: Data from the Swedish Heart Failure Registry
- Retrospective cohort study
- registry-based
Authors' conclusion
In a large and contemporary real-world HFrEF cohort, we estimated that 21.4% of patients would be eligible for vericiguat according to the VICTORIA trial selection criteria, 47.4% based on guidelines and labelling.
Study context
- Population
- Patients with HF with reduced ejection fraction (HFrEF) and heart failure (HF) duration ≥6 months, Swedish HF registry, enrolled 2000–2018
- Participants
- 23,573 patients
- Exposure
- Vericiguat eligibility by trial vs guideline vs label criteria
- Outcome
- Estimated eligibility for vericiguat
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
Most limiting criterion: prior HF hospitalization within 6 months
- Criterion limiting eligibility the most in all scenarios; met by % of population
- 49.1%
- Other meaningful limiting criteria in trial scenario: elevated NT-proBNP and nitrate use
Eligibility, hospitalized vs non-hospitalized for HF at baseline (subgroup)
- Trial scenario: hospitalized vs non-hospitalized
- 44.3% vs. 21.4%
- Guideline/label scenarios: hospitalized vs non-hospitalized
- 97.3% vs. 47.4%
Characteristics and outcomes, eligible vs ineligible
- Eligible patients older, more severe HF, more comorbidities, higher CV mortality and HF hospitalization rates across all scenarios
Original publication
Eligibility for Vericiguat in a Real-World Heart Failure Population According to Trial, Guideline and Label Criteria: Data from the Swedish Heart Failure Registry. Eur J Heart Fail. Published 29 June 2023. doi:10.1002/ejhf.2939
Summarised from the published abstract; every number is checked against it